Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Tafasitamab Biosimilar - Anti-CD19 mAb - Research Grade |
---|---|
Source | CAS 1422527-84-1 |
Species | Humanized |
Expression system | Mammalian cells |
Purity | >85% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Applications | ELISA,WB |
Aliases /Synonyms | Tafasitamab,MOR-00208,MOR-208,XENP-5574,XMP-5574,XmAb-5574,Xmab-CD19,CD19,anti-CD19 |
Reference | PX-TA1365 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1-G2-kappa |
Clonality | Monoclonal Antibody |
Tafasitamab is a humanized monoclonal antibody that targets CD19. It is used for the treatment of B-cell malignancies. The CD19 surface protein is highly expressed on the surface of B-cells where it enhances B-cell receptor signaling. CD19 is especially expressed in cases of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL). By its activity, tafasatimab induces the lysis of B-cells.
Tafasitamab Biosimilar - Anti-CD19 mAb, on SDS-PAGE under non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Related products
Reviews
Il n’y a pas encore d’avis.